Clinical trials: in Republic of the Congo
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Stress Disorders, Post-Traumatic, Depression
Psychological and Psychosocial Intervention With War-Affected Children
The investigators are interested in knowing whether a group-based, trauma-focused intervention (Trauma Focused Cognitive Behavioral Therapy) is superior to a more general, non trauma-focused, psychosocial intervention (Child…
- Conditions
- Stress Disorders, Post-Traumatic, Depression, Anxiety, Conduct
- Trial name
- NCT01509872
- Testing
- Trauma Focused Cognitive Behavioral Therapy, Child Friendly Space
- Where
- Republic of the Congo
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Psychological Distress
A Family-based, Resilience-focused Intervention for War-affected Communities in North-eastern Democratic Republic of Congo
The main research question of the study is whether a family-based, life-skills focused psychosocial intervention is effective in reducing psychological distress and stigma and improving inter-personal relations and functioning…
- Trial name
- NCT01542398
- Testing
- Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention
- Where
- Republic of the Congo
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Acute Uncomplicated Falciparum Malaria
Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg
The purpose of the study is to obtain efficacy, safety and pharmacokinetic (PK) data following treatment with artemether-lumefantrine dispersible tablet in infants < 5 kg of body weight (BW) with uncomplicated falciparum malaria.
- Trial name
- NCT01619878
- Testing
- Artemether-lumefantrine (COA566)
- Where
- 7 sites in Benin, Burkina Faso and 3 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals